A study of the cost analysis of various oral antihypertensive drugs available in Indian market
Keywords:Antihypertensive drugs, Cost analysis, Hypertension, Pharmacoeconomics
Background: Hypertension is a serious global public health problem. It accounts for 10% of all deaths in India and is the leading non-communicable disease. Recent studies have shown that the prevalence of hypertension is 25% in urban and 10% in rural people in India. It exerts a substantial public health burden on cardiovascular health status and health care systems in India. Antihypertensive treatment effectively reduces hypertension related morbidity and mortality. The cost of medications has always been a barrier to effective treatment. The increasing prevalence of hypertension requires use of cost effective treatment for the effective management of the disease.
Methods: Cost of a particular drug (cost per 10 tablets) in the same strength and dosage forms being manufactured by different companies was obtained from Current Index of Medical Specialties, Jan‑April 2019 and “Indian Drug Review” (IDR) September 2018. Difference between the maximum and minimum cost of the same drug manufactured by different pharmaceutical companies was calculated and percentage cost variation was calculated.
Results: The prices of a total of 24 drugs (15 single and 9 combination preparations), available in 59 different formulations were analysed. These 62 formulations are manufactured by different pharmaceutical companies.Conclusions: The average percentage price variation of different brands of the same oral antihypertensive drug manufactured in India is very wide. The appraisal and management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative personal and economic consequences.
Collins R, Peto R, MacMahon S, Godwin J, Qizilbash N, Hebert P, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335(8693):827-38.
Hansson L. The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens. 1996,14(5),537-44.
Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347-60.
Lewington S, Clarke R, Qizilbash N, et al. Age specific relevance of usual blood pressure to vascular mortality; a met-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360(9349):1903-13
Neal B. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356(9246):1955-64.
Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001, 358, 1305-15.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Ind J Pharm Sci. 2007;69(1):160-3.
Patel D, Thiyagu R, Surulivelrajan M, Patel H, Pandey S. Price variability among the oral antibiotics available in a South Indian Tertiary Care Hospital. J Clin Diagn Res. 2009;3(6):1871-5.
Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. J Inst Med. 2006;28(3):35-8.
Karve AV, Chattar KB. Cost analysis study of oral antihypertensive agents available in Indian market. Int J Basic Clin Pharmacol. 2014;3(3):479-83.
Planning Commission Report. Government of India 2014. Available at: http://www.planningcommission.nic.in/reports/genrep/por_rep0707.pdf.
Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India. 2004;17(2):80-3.
Sanchez LS. Pharmacoeconomics: Principles, methods and applications. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML. Eds. Pharmacotherapy: A pathophysiological approach. 7th ed. New York, NY: McGraw-Hill; 2008:179-201.
Food and Drug Administration and the Department of Health and Human Services. Notice. Guidance for Industry on Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims; Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm075072.pdf). Accessed 15 March 2011.
Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076-80.
Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Elsevier. Mayo Clin Proc. 2013;88(10):1099-1107.
Calhoun DA, Booth III JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63(3):451-8.
R Gupta. Trends in hypertension epidemiology in India. J Hum Hypertens. 2004;18(2):73-78.
Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004;291(15):1850-56.
Thomas M. Rational drug use and essential drug concept. In: Parthasarthi G, Nyfort Hasen K, editors. A Textbook of Clinical Pharmacy Practice. 1st ed. Himayatnagar, Hyderabad: Orient Longman; 2004:72-73.
Gialama F, Maniadakis N. Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan. Vasc Health Risk Manag. 2013;9:575-592.
Huang Y, Zhou Q, Haaijer-Ruskamp FM, Postma MJ. Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review. BMC Nephrol. 2014;15(1):15.
Miller L, Wade R, Dai D, et al. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension. Curr Med Res Opin. 2010;26(6):1307- 20.
Chen R, Lapuerta P. Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents. Curr Hypertens Rep. 2000;2(6):525-9.